Phospholipids in the Phospholipids in the management of autism management of autism

and degenerative and degenerative neurological diseasesneurological diseases

Victor A Marcial-Vega,MDVictor A Marcial-Vega,MDwww.marcialvegamd.commarcialvegamd@aol.com

Orlando,Florida, 2013Orlando,Florida, 2013

President’s Cancer Panel President’s Cancer Panel Report 2010Report 2010

Integrative Medicine Integrative Medicine CentersCenters

Cleveland ClinicCleveland Clinic Johns Hopkins HospitalJohns Hopkins Hospital UCLAUCLA George Washington UniversityGeorge Washington University MD Anderson Cancer CenterMD Anderson Cancer Center MSK Cancer CenterMSK Cancer Center Massage, Nutrition, Acupunture, Massage, Nutrition, Acupunture,

PsycotherapyPsycotherapy

Integrative MedicineIntegrative Medicine

Recognizes a crucial Recognizes a crucial environmental role of toxins in the environmental role of toxins in the etiology and/or worsening of most etiology and/or worsening of most diseasesdiseases

Ex. Carbon-Petroleum based Ex. Carbon-Petroleum based energy production, plastics, energy production, plastics, pesticides, heavy metals.pesticides, heavy metals.

Heavy MetalsHeavy Metals

Present in 100% of the populationPresent in 100% of the population Marker of other toxins present in Marker of other toxins present in

organismorganism Higgins, 2012- Parts per trillion of Higgins, 2012- Parts per trillion of

mercury significant (up to mercury significant (up to 1/1,000,000,000,000) significant in 1/1,000,000,000,000) significant in production of diseaseproduction of disease

24 hour urine collections24 hour urine collectionsPuerto Rico, 2008-2012Puerto Rico, 2008-2012Marcial-Vega, et al, 2013Marcial-Vega, et al, 2013

mmmmmmmmmm

Metals % from 51 patients

Range(ug/g creatinine)

Lead 100% 52/52 0.1 - 79.1

Mercury 65% 34/52 0.3 - 12.30

Aluminum 92% 48/52 0.8 - 77.4

Arsenic 100% 52/52 1 - 105

Cadmium 98% 51/52 0.05 - 16.09

Gadolinium 71% 37/52 0.005 - 93.5

Nickel 65% 34/52 0.2 - 15.39

Uranium 33% 17/52 0.008 - .2

Pre and Post EDTA Pre and Post EDTA CalciumCalcium

metals pre post

Lead 1.0 62.2

Mercury 0.55 2.87

Aluminum 0.131 77.4

Arsenic 6 17

Gadolinium 0.844 78

Nickel 0.91 0

Uranium 0 0.183

PROVOCATION WITH EDTAPROVOCATION WITH EDTA

Conventional medicine discourages Conventional medicine discourages provocation because of increased provocation because of increased toxicitytoxicity

They recommend diagnosis with They recommend diagnosis with bloodblood

We have found the oppositeWe have found the opposite It is both diagnostic and therapeutic It is both diagnostic and therapeutic

under strict nutritional conditions under strict nutritional conditions

IV Push with EDTA CalciumIV Push with EDTA Calcium

245 patients245 patients 2010-20132010-2013 Median Age 57Median Age 57 Dose range 300-3000 mgDose range 300-3000 mg Median 2.4 gramsMedian 2.4 grams

IV Push with EDTA CalciumIV Push with EDTA Calcium

5 minute infusion/once a week5 minute infusion/once a week Lowering of total cholesterol, LDL 85%Lowering of total cholesterol, LDL 85% Lowering of glucose levels 92%Lowering of glucose levels 92% Disappearance of joint pains 95%Disappearance of joint pains 95% More energy and sleeping better 100%More energy and sleeping better 100%

Marcial-Vega, 2013 Marcial-Vega, 2013

Retrospective Review Retrospective Review of a Rejuvenation of a Rejuvenation

Program in the Program in the Management of Management of

CancerCancer

Victor A. Marcial-Vega, MDVictor A. Marcial-Vega, MDwww.marcialvegamd.com

San Juan, Puerto RicoSan Juan, Puerto Rico

April 2013April 2013

Treatment ProtocolTreatment Protocol

Nutritional SupplementationNutritional Supplementation Intravenous Vitamin C (+ or Intravenous Vitamin C (+ or

- EDTA)- EDTA) Ozone/Hyperthermia Ozone/Hyperthermia

showersshowers

Intravenous Intravenous TherapyTherapy

Vitamin C 20 gramsVitamin C 20 grams Vitamins B1, B6(100 mg), Vitamins B1, B6(100 mg),

B12 (1000ug)B12 (1000ug) Sterile water(250 cc)Sterile water(250 cc) EDTA 2-6 cc(3g/21ccEDTA 2-6 cc(3g/21cc))

Intravenous Intravenous TherapyTherapy

Three times a weekThree times a week 20 gram weekly increases 20 gram weekly increases

until 70 grams or tolerance until 70 grams or tolerance is reachedis reached

Dose range 50-70 gramsDose range 50-70 grams

Ozone/Ozone/Hyperthermia Hyperthermia

ShowersShowers5 days a week5 days a week1/2 hour treatments1/2 hour treatments98-103 degrees 98-103 degrees FahrenheitFahrenheit

ResultsResultsAge Range 8-80 years Age Range 8-80 years Median 56 yearsMedian 56 years

Median Follow-up 18 Median Follow-up 18 monthsmonths

Analysis on 40 patientsAnalysis on 40 patients

Initial ResponseInitial Response More than 50% More than 50%

reduction of reduction of tumortumor

Within 3 weeksWithin 3 weeks (A) 25/33= 76%(A) 25/33= 76% (B) 3/5 = 60%(B) 3/5 = 60% (C) 1/2 = 50%(C) 1/2 = 50% Overall = 72%Overall = 72%

18 months results18 months results No tumor after No tumor after

multiple multiple recurrences 2/33recurrences 2/33

Complete Complete Response 6/33Response 6/33

Partial 6/33Partial 6/33 Total Total

14/33=42%14/33=42%

SymptomsSymptoms Improvement in 80% first Improvement in 80% first

2 weeks2 weeks Sustained at 5 months in Sustained at 5 months in

50%50%

Memory and AwarenessMemory and Awareness

Most patients report an Most patients report an improvement in cognitive, memory improvement in cognitive, memory and focusingand focusing

Brain characteristicsBrain characteristics This is an indicator of correlation This is an indicator of correlation

between toxins and brain functionbetween toxins and brain function

PhospholipidsPhospholipids

PlaquexPlaquex In the management of In the management of

cardiovascular diseases and cardiovascular diseases and detoxificationdetoxification

Our clinic in Miami started Our clinic in Miami started managing and detoxing patients managing and detoxing patients with IV phosphatidylcholinewith IV phosphatidylcholine

Neurological Diseases Neurological Diseases AdultsAdults

More than 85% of Alzheimer’s More than 85% of Alzheimer’s Disease patients will have an MRI Disease patients will have an MRI or CT scan showing white matter or CT scan showing white matter changes consistent with small changes consistent with small vessel ischemic disease.vessel ischemic disease.

A disease of brain toxicityA disease of brain toxicity Fourth leading cause of death in Fourth leading cause of death in

Puerto Rico. 6Puerto Rico. 6thth in the USA in the USA

Alzheimer’s DiseaseAlzheimer’s Disease

Gochi, Chlorella, Vitamin C and Gochi, Chlorella, Vitamin C and LactobacillusLactobacillus

Alkalinizing ProgramAlkalinizing Program Intravenous phosphatidylcholineIntravenous phosphatidylcholine 250-1500 mg IV Push or IV bag in 250-1500 mg IV Push or IV bag in

D5WD5W B12, GlutathioneB12, Glutathione WeeklyWeekly

Alzheimer’sAlzheimer’s

25 patients25 patients Marked improvement in 72% of the Marked improvement in 72% of the

patientspatients 2 had no response (8%)2 had no response (8%) 20% Moderate response20% Moderate response EDTA and PhosphatidylcholineEDTA and Phosphatidylcholine

DementiaDementia

10 patients 10 patients Marked improvement in most of Marked improvement in most of

their cognitive capacitiestheir cognitive capacities Improvement in socialization and Improvement in socialization and

orientation to placeorientation to place Last aspect to improve-Short term Last aspect to improve-Short term

memorymemory

Parkinson’s DiseaseParkinson’s Disease

5 patients5 patients Steady improvement in the first 2 Steady improvement in the first 2

months in 3/5months in 3/5 1 patient –No change1 patient –No change 1 patient-Dramatic improvement and 1 patient-Dramatic improvement and

reversal of all symptoms with PTC and reversal of all symptoms with PTC and pulsed electromagnetic frequencypulsed electromagnetic frequency

All patients now get PEMFAll patients now get PEMF

Chemotherapy Induced Chemotherapy Induced NeuropathyNeuropathy

Cisplatin, Carboplatin associatedCisplatin, Carboplatin associated Very painfulVery painful Feet and handsFeet and hands Does not respond well to Does not respond well to

analgesicsanalgesics

NeuropathyNeuropathy

Management with Management with phosphatidylcholinephosphatidylcholine

10 patients10 patients WeeklyWeekly Improvement in all patients in the Improvement in all patients in the

first two treatmentsfirst two treatments Complete Resolution of pain in 8 pts.Complete Resolution of pain in 8 pts. The earlier the betterThe earlier the better

ALSALS

8 patients8 patients One-EDTA, IVC, H2O2-no response. One-EDTA, IVC, H2O2-no response.

Died in less than a year Died in less than a year 2 more with PTC-No response2 more with PTC-No response 1 Pt. with 3x/day tx 15 txs. Week1 Pt. with 3x/day tx 15 txs. Week First week regained vocal cord and First week regained vocal cord and

swallowing movementswallowing movement

ALSALS

Stopped treatment after 3 months Stopped treatment after 3 months and deterioratedand deteriorated

One patient was stable for one One patient was stable for one year speaking and walking. Died year speaking and walking. Died from a fall from a fall

One patient improved and One patient improved and spasticity markedly improved with spasticity markedly improved with PTC and PEMFPTC and PEMF

ALSALS

Latest 2 patientsLatest 2 patients #1 in less than 2 weeks could #1 in less than 2 weeks could

understand previously unintelligible understand previously unintelligible speech. Swallowing better. speech. Swallowing better.

Improved pulmonary function studiesImproved pulmonary function studies #2 Could move extremities better in #2 Could move extremities better in

2 weeks2 weeks Both had daily treatmentBoth had daily treatment

Side EffectsSide Effects

Temporary (minutes) dizziness-2Temporary (minutes) dizziness-2 Extravasation and burning that Extravasation and burning that

would last days, weeks and would last days, weeks and sclerose veins temporarily 4%sclerose veins temporarily 4%

Months of sclerosing 3 patientsMonths of sclerosing 3 patients

AUTISMAUTISM

1:37 in Puerto Rico1:37 in Puerto Rico 1:50-75 in the USA1:50-75 in the USA No more figures presented in CDC No more figures presented in CDC

website since 2008website since 2008 Rapidly rising epidemicRapidly rising epidemic Maybe related to aluminum and Maybe related to aluminum and

mercury in vaccinesmercury in vaccines

AUTISMAUTISM

75 patients75 patients 7 Did not complete treatment7 Did not complete treatment Of the 68 remaining patientsOf the 68 remaining patients AnalysisAnalysis 75% trigered at 18 months of age 75% trigered at 18 months of age

related to vaccine booster dosesrelated to vaccine booster doses

AUTISMAUTISM

Eliminate sugar, complex Eliminate sugar, complex carbohydratescarbohydrates

Start nutritional alkalinizationStart nutritional alkalinization Intravenous phosphatidylcholineIntravenous phosphatidylcholine 250-1000 mg a week250-1000 mg a week Glutathione IV 400 mg a weekGlutathione IV 400 mg a week Methylcobalamin 1000 ugMethylcobalamin 1000 ug Folic acid 4 mgFolic acid 4 mg

AUTISMAUTISM

After 10-20 Weekly treatmentsAfter 10-20 Weekly treatments IV Phenylbutyrate 100-400 mg in 100 IV Phenylbutyrate 100-400 mg in 100

cc/d5wcc/d5w Continue if there was a steady Continue if there was a steady

improvementimprovement Side effects- Rash in 2 patients. Side effects- Rash in 2 patients.

Glutathione eliminated in them and it Glutathione eliminated in them and it resolved. They were both allergic to resolved. They were both allergic to eggseggs

RESULTSRESULTS

Frederick’s AtaxiaFrederick’s Ataxia

Hereditary diseaseHereditary disease Poor prognosisPoor prognosis Progressive Degenerative DiseaseProgressive Degenerative Disease 2 sisters 14, 16 years old2 sisters 14, 16 years old 5 treatments so far5 treatments so far Improvement in gait, fine motor Improvement in gait, fine motor

movements and energy levelsmovements and energy levels

CONCLUSIONSCONCLUSIONS

Phospholipid therapy reverses the Phospholipid therapy reverses the pathologic features of autism and pathologic features of autism and other neurological diseasesother neurological diseases

Phenylbutyrate seems to detoxify Phenylbutyrate seems to detoxify the brain and has a calming effect the brain and has a calming effect in all patientsin all patients

One to two years of therapy may One to two years of therapy may reverse all symptoms completelyreverse all symptoms completely

CONCLUSIONSCONCLUSIONS

Minimal side effects (allergic Minimal side effects (allergic reaction and itching in one patient)reaction and itching in one patient)